ContraFect Corp

22R

Company Profile

  • Business description

    ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

  • Contact

    28 Wells Avenue
    3rd Floor
    YonkersNY10701
    USA

    T: +1 914 207-2300

    E: [email protected]

    https://www.contrafect.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    23

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,057.6048.70-0.53%
CAC 407,830.1641.86-0.53%
DAX 4023,679.1667.830.29%
Dow JONES (US)46,437.07144.290.31%
FTSE 1009,249.5126.190.28%
HKSE26,518.65359.531.37%
NASDAQ22,594.8521.380.09%
Nikkei 22545,630.31136.650.30%
NZX 50 Index13,181.3144.770.34%
S&P 5006,666.289.360.14%
S&P/ASX 2008,764.5050.50-0.57%
SSE Composite Index3,853.6431.810.83%

Market Movers